BrandonMTriplettMD

Pediatric Hematology & Oncology • Memphis, TN

Physician

Join to view full profile

Dr. Triplett is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Triplett's full profile

Already have an account?

Office
262 Danny Thomas Pl
Memphis, TN 38105
Phone+1 888-226-4343

Education & Training

University of TennesseeFellowship, Pediatric Hematology/Oncology, 2003 - 2006
SSM Health/Saint Louis University School of MedicineResidency, Pediatrics, 2000 - 2003
Saint Louis University School of MedicineClass of 2000

Certifications & Licensure

TN State Medical License 2004 - 2026
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies Start of enrollment: 2007 Dec 14
Completed
Phase 2
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy Start of enrollment: 2013 May 16
Completed
Phase 2
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Start of enrollment: 2014 Oct 01
Terminated
Phase 2
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Start of enrollment: 2016 Jul 14
Recruiting
Phase 2
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Start of enrollment: 2019 Jan 31
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy.
Dua'a Zandaki, Subodh Selukar, Yu Bi, Ying Li, Megan Zinsky
Blood Advances. 2025-01-28
Safety and Efficacy of High-Dose Memory CD45RODonor Lymphocyte Infusion in Pediatric Recipients after Hematopoietic Stem Cell Transplantation.
Mercedes Gasior Kabat, Ying Li, Victor Galán, Yasmina Mozo, Luisa Sisinni
Cytotherapy. 2024-12-01
Blinatumomab infusion interruptions in pediatric patients rarely lead to readmission.
Jonathan Moody, Patricia J Barker, Joseph Sciasci, Jennifer L Pauley, Allison Bragg
Pediatric Blood & Cancer. 2024-10-01

Journal Articles

Selective T‐Cell Depletion Targeting CD45RA Reduces Viremia and Enhances Early T‐Cell Recovery Compared with CD3‐Targeted T‐Cell Depletion
Brandon M Triplett, David R Shook, Ewelina Mamcarz, Randall T Hayden, Shane J Cross, Ashok Srinivasan, Transplant Infectious Disease

Abstracts/Posters

Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing P...
Brandon Triplett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019